Christopher James Frankenfield, Chief Financial Officer at Xilio Therapeutics, Inc. (XLO), sold 14,060 shares at $0.64 ($9K) on 2026-01-02, disclosed to the SEC on 2026-01-05.
Open-market sale of $9k XLO by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.64 | 7,030 | $4K | 49.9% |
| 2 | $0.64 | 7,030 | $5K | 50.1% |
| Total | $0.64 avg | 14,060 | $9K | 100% |